Society for Clinical Research Sites Welcomes Myoderm as New Global Impact Partner
Ellicott City, M.D., May 11, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year collaboration with Myoderm, a global leader and specialist in sourcing, distribution, and management of comparator drugs and other pharmaceutical products and supplies for clinical research. Myoderm will participate as a Global Impact Partner (GIP) and align with sponsors, CROs and other industry solution providers who share an ongoing commitment to promoting site sustainability across the clinical trials landscape.
“SCRS is pleased to welcome Myoderm as our newest Global Impact Partner,” comments Christine Pierre, SCRS President. “Collaboration with Myoderm will incite dialogue around drug and product sourcing for clinical trials; factors which can affect individual sites. Myoderm has supply chain experience that factors into trial design, and can be shared to gain efficiencies in the processes currently being used.”
“We are honored to be a part of and collaborate with such an innovative organization and group of professionals,” Michael Cohen, Managing Director of Myoderm, remarks. “For more than 25 years we have focused on developing clinical trial supply solutions for sponsors, CROs and research sites alike. We see this partnership as an opportunity to make further advancements to the supply chain, alleviating pressure on research sites and positively impacting patients that benefit from new therapies being developed.”
As a Global Impact Partner (GIP), Myoderm will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
